Molecular Pharmacology (USA), Ltd.
MLPH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 6/30/2014 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | -0.00 | 0.00 | 0.19 |
| FCF Yield | 0.00% | 0.00% | 0.00% | -9.45% |
| EV / EBITDA | 0.00 | 0.00 | 0.00 | -9.52 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 457.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 0.98 | 0.99 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 48.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |